Platelet-activating factor contributes to postischemic vasospasm

Area of Science:

• Cardiovascular Research
• Microcirculation Physiology
• Inflammation Biology

Background:

• Skeletal muscle ischemia/reperfusion (I/R) injury can lead to significant microvascular dysfunction.
• The role of platelet-activating factor (PAF) in mediating I/R-induced vasospasm in skeletal muscle requires elucidation.

Purpose of the Study:

• To investigate whether platelet-activating factor (PAF) is a key mediator of vasospasm during skeletal muscle reperfusion following ischemia.
• To assess the impact of inhibiting specific inflammatory pathways on I/R-induced microcirculatory changes.

Main Methods:

• Utilized a rat cremaster muscle model with isolated vasculature and intraarterial drug infusion.
• Measured arteriole diameter and capillary perfusion via intravital microscopy.
• Administered PAF, cyclooxygenase inhibitor (indomethacin), thromboxane synthetase inhibitor (imidazole), nitric oxide synthase inhibitor (L-NAME), and a PAF receptor antagonist (CV-3988).

Main Results:

• PAF infusion caused mild, dose-dependent vasoconstriction.
• Indomethacin and imidazole pretreatment enhanced vasodilation to PAF.
• Nitric oxide inhibition potentiated PAF-induced vasoconstriction.
• Pretreatment with CV-3988, indomethacin, or imidazole significantly reduced I/R-induced vasospasm and capillary no-reflow.

Conclusions:

• Platelet-activating factor (PAF) plays a significant role in mediating vasoconstriction during skeletal muscle ischemia/reperfusion.
• Thromboxane A2 is also implicated in I/R-induced vasoconstriction.
• Inhibition of PAF and thromboxane A2 pathways offers a potential therapeutic strategy to mitigate skeletal muscle I/R injury.